---
schema_version: "secwatch.filing_event.v1"
accession: "0001127537-21-000037"
form_type: "8-K"
ticker: "LUNG"
cik: "0001127537"
company_name: "Pulmonx Corp"
filed_at: "2021-08-03T23:59:59+00:00"
generated_at: "2026-06-29T23:05:44.586514+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pulmonx Q2 2021 revenue $12.2M (+232% YoY); raises FY guidance to $49-51M

## Summary
- Worldwide revenue $12.2M, up 232% YoY; U.S. revenue $6.6M (+343%), international $5.6M (+157%).
- Gross margin 74% vs 28% a year ago; net loss $12.4M ($0.34 per share) vs $11.9M ($6.15).
- Added 20 new U.S. Zephyr Valve treating centers (total 180); launched Chartis software upgrade.
- FY 2021 revenue guidance raised to $49-51M from $48-50M; OpEx unchanged at $85-90M.
- Cash and marketable securities $211.5M as of June 30, 2021.

## SEC filing metadata
- accession: 0001127537-21-000037
- form_type: 8-K
- ticker: LUNG
- cik: 0001127537
- company_name: Pulmonx Corp
- filed_at: 2021-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1127537/000112753721000037/0001127537-21-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1127537/000112753721000037/lung-20210803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001127537-21-000037
- JSON: https://secwatch.observer/filing/0001127537-21-000037.json
- Plain text: https://secwatch.observer/filing/0001127537-21-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.